Dyne Therapeutics (NASDAQ:DYN) Earns Outperform Rating from Analysts at Oppenheimer
Stock analysts at Oppenheimer initiated coverage on shares of Dyne Therapeutics (NASDAQ:DYN – Get Free Report) in a research report issued on Monday, Marketbeat.com reports. The brokerage set an “outperform” rating and a $34.00 price target on the stock. Oppenheimer’s target price suggests a potential upside of 156.22% from the company’s current price. Other research […]
Stock analysts at Oppenheimer initiated coverage on shares of Dyne Therapeutics (NASDAQ:DYN – Get Free Report) in a research report issued on Monday, Marketbeat.com reports. The brokerage set an “outperform” rating and a $34.00 price target on the stock. Oppenheimer’s target price suggests a potential upside of 156.22% from the company’s current price. Other research […]
